[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340882-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340882-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bcl3-rearrangements-in-b-cell-lymphoid-neoplasms-occur-in-two-breakpoint-clusters-associated-with-different-diseases","BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters - Associated with different diseases","","BCL3 rearrangements in B-cell lymphoid neoplasms are analyzed through integrative whole-genome sequencing, transcriptomics, and DNA methylation in 13 BCL3-R cases. Single base-pair breakpoint mapping shows two breakpoint clusters at the 5′ (n=9) and 3′ (n=4) regions of BCL3, forming distinct biological and clinical entities. Aberrant IGH class switch recombination drives both events, yet 5′ breakpoints juxtapose BCL3 with an IGH enhancer and trigger gene overexpression. In contrast, 3′ breakpoints place BCL3 outside IGH influence without gene expression, yielding different molecular and clinical profiles, including atypical CLL morphology for upstream tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bcl3-rearrangements-in-b-cell-lymphoid-neoplasms-occur-in-two-breakpoint-clusters-associated-with-different-diseases/340882/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bcl3-rearrangements-in-b-cell-lymphoid-neoplasms-occur-in-two-breakpoint-clusters-associated-with-different-diseases/340882.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What methodology is used to study BCL3-R in lymphoid neoplasms?","Question",{"text":63,"@type":64},"The study uses integrative whole-genome sequencing, transcriptomic profiling, and DNA methylation analysis across 13 BCL3-R lymphoid neoplasms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many breakpoint clusters in BCL3 are observed, and where are they located?",{"text":68,"@type":64},"Breakpoints form two clusters at the 5′ region (n=9) and the 3′ region (n=4) of BCL3.",{"name":70,"@type":61,"acceptedAnswer":71},"Do upstream and downstream BCL3 breakpoints affect BCL3 expression differently?",{"text":72,"@type":64},"Yes. Upstream 5′ breakpoints juxtapose BCL3 with an IGH enhancer leading to BCL3 overexpression, while downstream 3′ breakpoints position BCL3 outside IGH influence and are not associated with expression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340882,1790247161,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","ARTICLE-Chronic Lymphocytic Leukemia  \nBCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases  \nAnna Carbó-Meix,1* Francesca Guijarro,1,2* Luojun Wang,2* Marta Grau,1* Romina Royo,3 Gerard Frigola,1,2 Heribert Playa-Albinyana,1,4 Marco M. Bühler,5 Guillem Clot,1 Martí DuranFerrer,1,4 Junyan Lu,6 Isabel Granada,7 Maria-Joao Baptista,7 José-Tomás Navarro,7 Blanca Espinet,8 Anna Puiggros,8 Gustavo Tapia,9 Laura Bandiera,10 Gabriella De Canal,10 Emanuela Bonoldi,10 Fina Climent,11 Inmaculada Ribera-Cortada,12 Mariana Fernández-Caballero,7 Esmeralda de la Banda,13 Janilson do Nascimento,14 Alberto Pineda,15 Dolors Vela,16 María Rozman,2 Marta Aymerich,1,2 Charlotte Syrykh,17 Pierre Brousset,17,18,19 Miguel Perera,20 Lucrecia Yáñez,21 Jesús Xavier Ortin,22 Esperanza Tuset,23 Thorsten Zenz,24 James R. Cook,25 Steven H. Swerdlow,26 José I. Martín-Subero,1,4,27,28 Dolors Colomer,1,2,4,27 Estella Matutes,2 Sílvia Beà,1,2,4,27 Dolors Costa,1,2,4 Ferran Nadeu1,4\\# and Elías Campo1,2,4,27\\#  \n1 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 2 Hematopathology Section, Pathology Laboratory, Hospital Clínic de Barcelona, Barcelona, Spain; 3 Barcelona Supercomputing Center (BSC), Barcelona, Spain; 4 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 5 Department of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland;  \n6 European Molecular Biology Laboratory, Heidelberg, Germany; 7 Department of Hematology, Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain; 8 Molecular Cytogenetics Laboratory, Department of Pathology, Hospital del Mar, Barcelona, Spain and Translational Research on Hematological Neoplasms Group (GRETNHE) -Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain; 9 Department of Pathology, Hospital Germans Trias i Pujol, Badalona, Spain; 10 Dipartimento Ematologia, Oncologia e Medicina Molecolare, Anatomia Istologia Patologica e Citogenetica, Niguarda Cancer Center, Milano, Italy; 11 Department of Pathology, Hospital Universitari de Bellvitge, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet De Llobregat, Spain; 12 Department of Pathology, Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, Principat d'Andorra; 13 Hematology Laboratory, Hospital Universitari Bellvitge, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet De Llobregat, Spain;  \n14 Department of Hematology, Hospital Joan XXIII, Institut Català d'Oncologia, Tarragona, Spain; 15 Department of Hematology, Fundació Hospital de l'Esperit Sant, Badalona, Spain; 16 Hematologia Clínica, Hospital General de Granollers, Granollers, Spain; 17 Department of Pathology, Toulouse University Hospital Center, Cancer Institute University of ToulouseOncopole, Toulouse, France; 18 INSERM UMR1037 Cancer Research Center of Toulouse (CRCT), ERL 5294 National Center for Scientific Research (CNRS), University of Toulouse III Paul-Sabatier, Toulouse, France; 19 Institut Carnot Lymphome CALYM, Laboratoire  \nd'Excellence 'TOUCAN', Toulouse, France; 20 Hematology Department, Hospital Dr Negrín, Las Palmas de Gran Canaria, Spain; 21 Hematology Department, Hospital Universitario Marqués de Valdecilla-Instituto de Investigación Valdecilla (IDIVAL), Santander, Spain; 22 Hematology Department, Hospital Verge de la Cinta, Tortosa, Spain; 23 Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain; 24 Department of Medical Oncology and Hematology, University Hospital and University of Zürich, Zurich, Switzerland; 25 Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA; 26 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 27 D","cbCaipDFoZ6mzW8r","https://ap.wps.com/l/cbCaipDFoZ6mzW8r","pdf",4954677,16,"English","# Abstract\n## Study design and cohorts\n## Breakpoint localization and clustering\n## Mechanistic basis via IGH class switch recombination\n## Divergent biological and clinical entities","[{\"question\":\"What methodology is used to study BCL3-R in lymphoid neoplasms?\",\"answer\":\"The study uses integrative whole-genome sequencing, transcriptomic profiling, and DNA methylation analysis across 13 BCL3-R lymphoid neoplasms.\"},{\"question\":\"How many breakpoint clusters in BCL3 are observed, and where are they located?\",\"answer\":\"Breakpoints form two clusters at the 5′ region (n=9) and the 3′ region (n=4) of BCL3.\"},{\"question\":\"Do upstream and downstream BCL3 breakpoints affect BCL3 expression differently?\",\"answer\":\"Yes. Upstream 5′ breakpoints juxtapose BCL3 with an IGH enhancer leading to BCL3 overexpression, while downstream 3′ breakpoints position BCL3 outside IGH influence and are not associated with expression.\"}]","BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters - Associated with different diseases | PDF",1790039312,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f94d8070221b4c92893f94ec1569f274.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a34a53ad65479cb5ce89467d27c4eeb7.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03e2ae5b7a19cd49e0c227361d00f46a.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fadb755abc2987c88d517b6fcb5d9c4a.webp",980,1306]